a community of healthcare providers, we should continue to foster the advancement of knowledge, so that we can bring more therapies to the bedside to improve the quality of life for patients. The only way to do this is to have a 100% commitment from the community to participate in these trials, to provide the highest level of quality data, and to be committed to the conduct and completion of the questions evaluating new approaches, diagnostics and therapeutics for our heart failure patients. The PRAISE-2 trial reminds us of an era when there was a great enthusiasm by the heart failure community to participate in clinical trials and achieve results quickly to answer questions. While PRAISE-2 was a neutral trial, it helped redirect our efforts into different directions and was highly informative in completing the body of knowledge regarding calcium channel antagonists in congestive heart failure. I hope by bringing this trial into the public arena, we are not only focusing on the results but also on the method of conduct of an important trial. The consortia approach of the DUCCS and SWANS should challenge us to bring back this era to the United States, where we are committed to advancing knowledge through site-based research.
